Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$40.03 USD
+0.04 (0.10%)
Updated Sep 18, 2024 03:58 PM ET
After-Market: $40.33 +0.30 (0.75%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 30% (74 out of 250)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 3.00 | 1.58 | 9.99 |
Current Quarter Estimate | -0.10 | -1.17 | 61.00 |
Year Ago Quarter Estimate | -0.58 | -0.06 | 54.84 |
Next Quarter Estimate | 0.12 | -1.92 | 63.00 |
Next Year Estimate | 3.61 | 12.59 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 50.61 | 20.00 | 15.67 |
Next Year | 545.68 | 15.30 | 11.34 |
Last 5 Years | NA | 7.80 | 8.10 |
Next 5 Years | NA | 20.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -1.44 |
Price/Book (MRQ) | 119.44 | 1.59 |
Price/Cash Flow (MRFY) | NA | 9.47 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -30.19% | -61.35% |
Return on Equity (TTM) | -212.05% | -58.93% |
Debt to Equity (MRQ) | 9.44 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.